Table of Contents 3
List of Tables 6
List of Figures 7
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Sumitomo Dainippon Pharma Co Ltd, Medical Devices Deals, 2012 to YTD 2018 13
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deal Details 19
Asset Purchase 19
Tolero Pharma Acquires Drug Development Assets From Astex Pharma 19
Venture Financing 21
Tolero Pharma Raises USD8.2 Million in Second Tranche of Series B Financing 21
Tolero Pharma Raises USD14.2 Million in Series B Venture Financing 22
Matrizyme Pharma Raises USD9 Million in Financing 23
Tolero Pharma Raises US$3.33 Million In Venture Financing 24
Elevation Pharma Secures US$30 Million In Series B Financing 25
Private Equity 27
Orbimed Advisors Acquires Additional 3.17% Stake in Cynapsus Therapeutics for USD6.3 Million 27
Partnerships 28
Tolero Pharma Enters into Research Agreement with AbbVie 28
Sumitomo Dainippon Pharma Enters into Research Agreement with Medicines for Malaria Venture 29
Carna Biosciences Enters into Development Agreement with Sumitomo Dainippon Pharma 30
Kitasato Institute Enters into Research Agreement with Sumitomo Dainippon Pharma 31
Takeda Pharma and Shionogi Enter into Research Agreement with Sumitomo Dainippon Pharma, Ono Pharma and Mitsubishi Tanabe Pharma 32
Sharp Edge Labs Enters into Agreement with Sumitomo Dainippon Pharma 34
FunPep Enters into Research Agreement with Sumitomo Dainippon 35
Dainippon Sumitomo Pharma Extends Research Agreement with CiRA and Hitachi 36
Eli Lilly Japan Partners with Sumitomo Dainippon Pharma 37
Japan Tobacco, Torii Pharmac and Sumitomo Dainippon Pharma Enter into Partnership 38
ex scientia Enters into Research Agreement with Sunovion Pharma 39
Dainippon Sumitomo Pharma Enters into Co-Marketing Agreement with Teikoku Seiyaku 40
Healios Forms Joint Venture With Dainippon Sumitomo Pharma 42
Eutropics Enters Into Co-Development Agreement With Tolero Pharma 43
Healios And Dainippon Sumitomo Pharma Enter Into Agreement For iPS Cell Technology 44
Sunovion Pharma Enters Into Agreement With Afraxis To Discover CNS Drugs 45
Dainippon Sumitomo Pharma Forms Joint Venture With Japan BCG Lab 46
PsychoGenics Extends Drug Discovery Agreement with Sunovion Pharma 47
Ono Pharma Expands Co -Development Agreement With Dainippon Sumitomo Pharma For Limaprost Alfadex 48
Dainippon Sumitomo Pharma Enters Into Research Agreement With Kobe University For Anti-Cancer Drugs 49
Prasco Labs Enters into Distribution Agreement with Sunovion Pharma for Xopenex 50
Licensing Agreements 51
Sumitomo Dainippon Pharma Enters into Licensing Agreement with JCR Pharma 51
Angelini Enters into Licensing and Distribution Agreement with Sunovion Pharma 52
Sumitomo Dainippon Pharma and Poxel Form Strategic Partnership for Development and Commercialization of Imeglimin 53
Maruishi Pharma Enters into Licensing Agreement with Sumitomo Dainippon Pharma 54
Sumitomo Dainippon Pharma Enters into Licensing Agreement with Bukwang Pharm 55
Sunovion Pharma Enters into Licensing Agreement with Novartis 56
Cynapsus Therapeutics Enters into Licensing Agreement with MonoSol Rx 57
Sumitomo Dainippon Pharma Enters into Licensing Agreement with Elixirgen 58
Sumitomo Dainippon Pharma Enters into Licensing Agreement with Servier Lab 59
SanBio Enters into Licensing Agreement with Sumitomo Dainippon Pharma for SB623 60
Dainippon Sumitomo Pharma Enters into Licensing Agreement with Daiichi Sankyo 62
Healios Enters Into Licensing Agreement With Dainippon Sumitomo Pharma For RPE Cells 63
Dainippon Sumitomo Pharma Enters into Licensing Agreement with Standard Chem. & Pharm 64
Tolero Pharma Enters Into Licensing Agreement With Sanofi For Alvocidib 65
Edison Pharma Expands Licensing Agreement With Dainippon Sumitomo Pharma 66
Dainippon Sumitomo Pharma Enters Into Licensing Agreement With Nippon Shinyaku For SMP-986 68
Dnavec Enters into Licensing Agreement with Sumitomo Dainippon Pharma 69
Kobe University And KNC Labs Enter Into Licensing Agreement With Dainippon Sumitomo Pharma 70
Dainippon Sumitomo Pharma Enters Into Licensing Agreement With Shionogi For DSP-8153 72
MannKind Enters Into Licensing Agreement With Tolero Pharma For Bruton’s Tyrosine Kinase Inhibitors 73
Equity Offering 74
Cynapsus Therapeutics Raises USD72.5 Million in Public Offering of Shares 74
Cynapsus Therapeutics Raises USD16.6 Million in Private Placement of Shares 76
Cynapsus Therapeutics Completes Public Offering Of Units For US$22.8 Million 78
Cynapsus Therapeutics Completes Second Tranche Of Private Placement Of Units For US$1.3 Million 79
Cynapsus Therapeutics Completes Private Placement Of Units For US$1 Million 81
Cynapsus Therapeutics Completes Private Placement Of Units For US$0.2 Million 82
Cynapsus Therapeutics Completes Private Placement Of Units For US$0.1 Million 83
Debt Offering 84
Cynapsus Therapeutics Completes Additional Public Offering Of Series E Debentures Due 2013 For US$1.1 Million 84
Asset Transactions 86
Sunovion Pharma to Divest US Rights of Ciclesonide Products to Covis Pharma 86
Akorn Acquires Xopenex Inhalation Solution from Sunovion Pharma for USD45 Million 87
Acquisition 88
Sumitomo Dainippon Pharma Acquires Tolero Pharma 88
Sunovion Pharma Acquires Cynapsus Therapeutics for up to USD635 Million 90
Dainippon Sumitomo Pharma To Acquire 5% Stake In Retina Institute Japan For US$16 Million 92
Sunovion Pharma Completes Acquisition Of Elevation Pharma For Up To US$430 Million 93
Dainippon Sumitomo Pharma Completes Acquisition Of Boston Biomedical 95
Sumitomo Dainippon Pharma Co Ltd - Key Competitors 97
Sumitomo Dainippon Pharma Co Ltd - Key Employees 98
Sumitomo Dainippon Pharma Co Ltd - Locations And Subsidiaries 100
Head Office 100
Other Locations & Subsidiaries 100
Recent Developments 103
Strategy And Business Planning 103
Mar 01, 2018: Sumitomo Dainippon Pharma Completes Manufacturing Plant for Regenerative Medicine & Cell Therapy 103
Financial Announcements 104
Oct 30, 2018: Sumitomo Dainippon: Consolidated financial results for the second quarter of the year ending March 31, 2019 104
Jul 27, 2018: Sumitomo Dainippon Pharma provides summary of consolidated financial results for the first quarter of the year ending March 31, 2019 107
May 11, 2018: Sumitomo Dainippon Pharma: Summary of Consolidated Financial Results for the Year Ended March 31, 2018 110
Corporate Communications 115
Sep 03, 2018: Sumitomo Dainippon Pharma announces personnel changes 115
Jun 28, 2018: Sumitomo Dainippon Pharma Contributes to Northern Osaka Earthquake Relief Efforts in Japan 116
Jun 15, 2018: Sumitomo Dainippon Pharma Announces Management Changes 117
May 11, 2018: Sumitomo Dainippon Pharma announces Changes in Board of Directors, Audit & Supervisory Board and Other Key Positions 118
Feb 23, 2018: Sumitomo Dainippon Pharma Names Hiroshi Nomura As President And CEO 119
Mar 29, 2017: Sumitomo Dainippon Pharma announces Changes in Executive Officers 120
Mar 22, 2017: Sumitomo Dainippon Pharma Announces New Chief Executive Officer at Boston Biomedical and Establishment of Global Head of Oncology 121
Legal and Regulatory 123
Jul 30, 2018: Kyoto University Hospital and the Center for iPS Cell Research and Application (CiRA) to begin physician-initiated clinical trials for parkinson’s disease 123
Government and Public Interest 124
Jun 01, 2017: Sumitomo Dainippon Pharma Contributes funding to the Global Health Innovative Technology Fund (GHIT Fund) for the Second Period 124
Product News 125
05/17/2018: Sumitomo Dainippon Pharma announces the Clinical Data will be presented at ASCO 2018 125
Product Approvals 126
Jul 10, 2017: Boston Biomedical Announces Orphan Drug Designation by FDA for Investigational WT1 Cancer Peptide Vaccine DSP-7888 in Myelodysplastic Syndrome 126
Feb 28, 2017: Sumitomo Dainippon Pharma announces Allogeneic iPS cell-derived Dopaminergic Neural Progenitor Cells Designated a “SAKIGAKE” Product by Japan’s Ministry of Health, Labour and Welfare 127
Clinical Trials 128
Jul 31, 2018: Kyoto University to begin trials of iPS cells to treat Parkinson’s 128
Jun 01, 2018: Boston Biomedical Highlights Presentations on Investigational Agent DSP-7888 (ombipepimut-S) at ASCO 2018 129
Apr 25, 2018: Boston Biomedical Initiates Two Studies Evaluating WT1 Cancer Peptide Vaccine DSP-7888 (ombipepimut-S) 130
Oct 10, 2017: Boston Biomedical Announces Orphan Drug Designation by FDA for Investigational WT1 Cancer Peptide Vaccine DSP-7888 in Brain Cancer 131
May 18, 2017: Sumitomo Dainippon Pharma to Present Clinical Data on WT-2725 at ASCO 2017 132
Other Significant Developments 133
May 31, 2018: Sumitomo Dainippon Pharma Joins IFPMA as New Member[TOPC : Pharma - Sumitomo Dainippon Pharma Co Ltd] 133
Jul 04, 2017: Sumitomo Dainippon Pharma Announces Change in Name of Consolidated Subsidiary Based in U.S. 134
Apr 10, 2017: Hitachi is selected by Sumitomo Dainippon Pharma for Automated Cell Mass Culture Equipment for Regenerative Medicine using Human iPS Cells 135
Appendix 136
Methodology 136
About GlobalData 136
Contact Us 136
Disclaimer 136

List of Tables
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Sumitomo Dainippon Pharma Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 11
Sumitomo Dainippon Pharma Co Ltd, Medical Devices Deals, 2012 to YTD 2018 13
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14
Tolero Pharma Acquires Drug Development Assets From Astex Pharma 19
Tolero Pharma Raises USD8.2 Million in Second Tranche of Series B Financing 21
Tolero Pharma Raises USD14.2 Million in Series B Venture Financing 22
Matrizyme Pharma Raises USD9 Million in Financing 23
Tolero Pharma Raises US$3.33 Million In Venture Financing 24
Elevation Pharma Secures US$30 Million In Series B Financing 25
Orbimed Advisors Acquires Additional 3.17% Stake in Cynapsus Therapeutics for USD6.3 Million 27
Tolero Pharma Enters into Research Agreement with AbbVie 28
Sumitomo Dainippon Pharma Enters into Research Agreement with Medicines for Malaria Venture 29
Carna Biosciences Enters into Development Agreement with Sumitomo Dainippon Pharma 30
Kitasato Institute Enters into Research Agreement with Sumitomo Dainippon Pharma 31
Takeda Pharma and Shionogi Enter into Research Agreement with Sumitomo Dainippon Pharma, Ono Pharma and Mitsubishi Tanabe Pharma 32
Sharp Edge Labs Enters into Agreement with Sumitomo Dainippon Pharma 34
FunPep Enters into Research Agreement with Sumitomo Dainippon 35
Dainippon Sumitomo Pharma Extends Research Agreement with CiRA and Hitachi 36
Eli Lilly Japan Partners with Sumitomo Dainippon Pharma 37
Japan Tobacco, Torii Pharmac and Sumitomo Dainippon Pharma Enter into Partnership 38
ex scientia Enters into Research Agreement with Sunovion Pharma 39
Dainippon Sumitomo Pharma Enters into Co-Marketing Agreement with Teikoku Seiyaku 40
Healios Forms Joint Venture With Dainippon Sumitomo Pharma 42
Eutropics Enters Into Co-Development Agreement With Tolero Pharma 43
Healios And Dainippon Sumitomo Pharma Enter Into Agreement For iPS Cell Technology 44
Sunovion Pharma Enters Into Agreement With Afraxis To Discover CNS Drugs 45
Dainippon Sumitomo Pharma Forms Joint Venture With Japan BCG Lab 46
PsychoGenics Extends Drug Discovery Agreement with Sunovion Pharma 47
Ono Pharma Expands Co -Development Agreement With Dainippon Sumitomo Pharma For Limaprost Alfadex 48
Dainippon Sumitomo Pharma Enters Into Research Agreement With Kobe University For Anti-Cancer Drugs 49
Prasco Labs Enters into Distribution Agreement with Sunovion Pharma for Xopenex 50
Sumitomo Dainippon Pharma Enters into Licensing Agreement with JCR Pharma 51
Angelini Enters into Licensing and Distribution Agreement with Sunovion Pharma 52
Sumitomo Dainippon Pharma and Poxel Form Strategic Partnership for Development and Commercialization of Imeglimin 53
Maruishi Pharma Enters into Licensing Agreement with Sumitomo Dainippon Pharma 54
Sumitomo Dainippon Pharma Enters into Licensing Agreement with Bukwang Pharm 55
Sunovion Pharma Enters into Licensing Agreement with Novartis 56
Cynapsus Therapeutics Enters into Licensing Agreement with MonoSol Rx 57
Sumitomo Dainippon Pharma Enters into Licensing Agreement with Elixirgen 58
Sumitomo Dainippon Pharma Enters into Licensing Agreement with Servier Lab 59
SanBio Enters into Licensing Agreement with Sumitomo Dainippon Pharma for SB623 60
Dainippon Sumitomo Pharma Enters into Licensing Agreement with Daiichi Sankyo 62
Healios Enters Into Licensing Agreement With Dainippon Sumitomo Pharma For RPE Cells 63
Dainippon Sumitomo Pharma Enters into Licensing Agreement with Standard Chem. & Pharm 64
Tolero Pharma Enters Into Licensing Agreement With Sanofi For Alvocidib 65
Edison Pharma Expands Licensing Agreement With Dainippon Sumitomo Pharma 66
Dainippon Sumitomo Pharma Enters Into Licensing Agreement With Nippon Shinyaku For SMP-986 68
Dnavec Enters into Licensing Agreement with Sumitomo Dainippon Pharma 69
Kobe University And KNC Labs Enter Into Licensing Agreement With Dainippon Sumitomo Pharma 70
Dainippon Sumitomo Pharma Enters Into Licensing Agreement With Shionogi For DSP-8153 72
MannKind Enters Into Licensing Agreement With Tolero Pharma For Bruton’s Tyrosine Kinase Inhibitors 73
Cynapsus Therapeutics Raises USD72.5 Million in Public Offering of Shares 74
Cynapsus Therapeutics Raises USD16.6 Million in Private Placement of Shares 76
Cynapsus Therapeutics Completes Public Offering Of Units For US$22.8 Million 78
Cynapsus Therapeutics Completes Second Tranche Of Private Placement Of Units For US$1.3 Million 79
Cynapsus Therapeutics Completes Private Placement Of Units For US$1 Million 81
Cynapsus Therapeutics Completes Private Placement Of Units For US$0.2 Million 82
Cynapsus Therapeutics Completes Private Placement Of Units For US$0.1 Million 83
Cynapsus Therapeutics Completes Additional Public Offering Of Series E Debentures Due 2013 For US$1.1 Million 84
Sunovion Pharma to Divest US Rights of Ciclesonide Products to Covis Pharma 86
Akorn Acquires Xopenex Inhalation Solution from Sunovion Pharma for USD45 Million 87
Sumitomo Dainippon Pharma Acquires Tolero Pharma 88
Sunovion Pharma Acquires Cynapsus Therapeutics for up to USD635 Million 90
Dainippon Sumitomo Pharma To Acquire 5% Stake In Retina Institute Japan For US$16 Million 92
Sunovion Pharma Completes Acquisition Of Elevation Pharma For Up To US$430 Million 93
Dainippon Sumitomo Pharma Completes Acquisition Of Boston Biomedical 95
Sumitomo Dainippon Pharma Co Ltd, Key Competitors 97
Sumitomo Dainippon Pharma Co Ltd, Key Employees 98
Sumitomo Dainippon Pharma Co Ltd, Other Locations 100
Sumitomo Dainippon Pharma Co Ltd, Subsidiaries 101

List of Figures
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Sumitomo Dainippon Pharma Co Ltd, Medical Devices Deals, 2012 to YTD 2018 13